Efficacy of ACE inhibitors in patients with recent myocardial infarction. Studies with zofenopril;Efficacia degli ACE-inibitori nei pazienti con recente infarto miocardico. Gli studi con zofenopril

Giornale Italiano di Cardiologia

Volumn 13, Issue 10 SUPPL.2, 2012, Pages

  Lombardi, Carlo ^a   Castrini, Anna Isotta ^a   Metra, Marco ^a   Carubelli, Valentina ^a   Lazzarini, Valentina ^a   Inama, Lorenza ^a   Cas, Livio Dei ^a  

^a SPEDALI CIVILI   (Italy)

Author keywords

ACE inhibitors; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; RAMIPRIL; ZOFENOPRIL;

DRUG EFFICACY; HEART INFARCTION; HOSPITALIZATION; PROGNOSIS; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; HUMANS; MYOCARDIAL INFARCTION; TIME FACTORS;

EID: 84872178534     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: 10.1714/1167.12922     Document Type: Review

References (30)

1. Spencer FA, Mayer TE, Goldberg RJ, et al. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999;34:1378-87.
2. Ellison KE, Gandhi G. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs 2005;65:787-97.
3. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
4. ACE Inhibitor Myocardial Infarction Collaborative Group. Indication for ACE-inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trial. Circulation 1998;97:2202-12.
5. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52.
6. Danser AH, Saris JJ, Schuijt MP, van Kats JP. Is there a local renin-angiotensin system in the heart? Cardiovasc Res 1999;44:252-65.
7. Neutel JM. Effect of the renin-angiotensin system on the vessels wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004;18:599-606.
8. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
9. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
10. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
11. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
12. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
13. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
14. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
15. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-bind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
16. Van de Werf E, Bax J, betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-45.
17. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999;17:115-33.
18. Przyklenk K, Kloner RA. "Cardioprotection" by ACE-inhibitors in acute myocardial ischemia and infarction? Basic Res Cardiol 1993;88(Suppl 1):139-54.
19. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J 1991;121:1319-30.
20. Westlin W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation 1988;77(6 Pt 2):I30-I39.
21. Liu X, Engelman RM, Rousou JA, Cordis GA, Das DK. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992;6:437-43.
22. de Nigris F, D'Armiento FP, Somma P, et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduces susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001;81:107-15.
23. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148:e5.
24. Ambrosioni E, Borghi C, Magnani B. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE Pilot Study Working Party. Am J Cardiol 1991;68:101D-110D.
25. Ambrosioni E, Borghi C, Magnani B. Survival of myocardial infarction long-term evaluation (SMILE) study: rationale, design, organization, and outcome definitions. Control Clin Trials 1994;15:201-10.
26. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-5.
27. Borghi C, Ambrosioni E; Survival of Myocardial infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003;145:80-7.
28. Borghi C, Ambrosioni E; Survival of Myocardial infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007;153:445.e7-14.
29. Borghi C, Ambrosioni C, Novo S, Vinereanu D, Ambrosio G. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol 2012;35:416-23.
30. Zhu BQ, Sievers RE, Browne AE, et al. Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. J Renin Angiotensin Aldosterone Syst 2003;4:31-7.